Windward Bio Secures $165 Million to Advance Long-Acting TSLP Antibody for Asthma and COPD

Immunology remains a lucrative and competitive field in biotech, with companies vying to develop innovative treatments for chronic conditions. Basel-based Windward Bio is the latest entrant to this arena, securing $165 million in crossover financing to advance its pipeline of long-acting immunology therapies. The company's lead candidate, WIN378, is a TSLP-blocking antibody designed to be administered every six months, potentially offering a significant dosing advantage over existing treatments.

WIN378 targets thymic stromal lymphopoietin (TSLP), a signaling protein that plays a critical role in driving immunological disorders such as asthma and chronic obstructive pulmonary disease (COPD). The drug is currently in Phase 2/3 clinical trials, with preliminary data expected in the second half of this year. If successful, WIN378 could challenge Tezspire, an existing TSLP-blocking antibody from Amgen and AstraZeneca that requires monthly injections.

Clinical Progress and Competitive Landscape

Windward's Phase 2 dose-ranging portion of the Phase 2/3 study is ongoing, with the company aiming to demonstrate both safety and efficacy. The Phase 3 portion of the trial is expected to begin in the fourth quarter of this year. A Phase 2 test for COPD is slated to start in the current quarter. These trials are crucial for validating WIN378's potential as a best-in-class therapy.

The competition in the TSLP-blocking antibody space is heating up. Upstream Bio is developing verekitug, which can be dosed every three months and potentially every six months. Generate Biomedicines, which went public earlier this year, is also working on a TSLP-blocking antibody designed for six-month intervals. Both companies are leveraging advanced biotechnology to improve patient convenience and treatment outcomes.

Windward's journey began last year with a $200 million Series A financing round, which funded the development of WIN378. The drug was licensed from Kelun-Biotech and Harbour Biomed, providing Windward with a strong foundation for its clinical programs. In late 2025, the company signed a deal to further bolster its pipeline, though details of this agreement were not disclosed.

Investment Implications

The $165 million crossover financing round is a significant vote of confidence in Windward's approach and the potential of WIN378. This funding will be crucial for advancing the drug through Phase 3 trials and preparing for potential regulatory submissions. The market for asthma and COPD treatments is substantial, with global sales estimated at billions of dollars annually.

Investors should watch closely as preliminary data from the Phase 2/3 study becomes available later this year. Positive results could catalyze further investment and partnerships, while any setbacks may impact Windward's valuation and development timeline. The company's ability to demonstrate a dosing advantage and superior efficacy will be key factors in its success.

In a highly competitive landscape, Windward must also navigate the challenges of clinical trial design, regulatory approval, and market entry. However, with robust funding and a promising lead candidate, the company is well-positioned to make significant strides in the immunology space.